| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 5.6 | 6.5 |
| Net income | -12.5 | -19.7 |
| EPS (diluted, $ a share) | $-0.12 | $-0.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -13.1% |
|---|---|
| Operating margin | -252.6% |
10-Q filed with the SEC, NASDAQ: PRLD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Prelude Therapeutics Inc: key numbers
- Share price
- $3.41Close, Nov 16
- Market cap
- $273M
- Shares outstanding
- 80.07MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Prelude Therapeutics Inc
All →Prelude Therapeutics Financial Results
Prelude Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $142.7 million which is expected to fund operations into Q2 2028. The company advanced its clinical pipeline with the initiation of a Phase 1 study for PRT13722 in breast cancer and entered a clinical collaboration with Eli Lilly to evaluate combination therapies.
“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer.”
Kris Vaddi, Ph.D., Chief Executive Officer of Prelude